The TP53 mutation was found to be the most significantly enriched genetic event in CRPC compared to hormone-sensitive stages of cancer21, which led us to hypothesize that the TP53 mutation is a powerful factor in driving the development of castration resistance in prostate cancer. This evidence concerns the gene TP53 and prostate cancer.